Evidence map›Paper›PMID 39955428›Full record

ArticleScientific reports2025

Distinct clinicopathological features and treatment differences in breast cancer patients of young age.

Rasmus O C Humlevik, Amalie A Svanøe, Turid Aas, Anette Heie, Anna K M Sæle, Lars A Akslen, Elisabeth Wik, Erling A Hoivik

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. CNR1 and CNR2 Cannabinoid Receptor Mutations in Cancer Cells.Current issues in molecular biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rasmus O C HumlevikCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway.
Amalie A SvanøeCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway.
Turid AasDepartment of Surgery, Haukeland University Hospital, Bergen, Norway.
Anette HeieDepartment of Surgery, Haukeland University Hospital, Bergen, Norway.
Anna K M SæleCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway.
Lars A AkslenCentre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway.
Elisabeth Wik *Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway.
Erling A Hoivik *Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of, Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Erling.Hoivik@uib.no.ORCID 0000-0003-0680-765X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of breast cancer in young women (aged under 40) is on the rise and is associated with more aggressive tumor characteristics and lower survival rates. Breast cancer is most frequently diagnosed in the sixth decade, and most research presents results based on data from older patients. By using large-scale clinico-pathologic and transcriptomic data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1932), we aimed to explore age-related differences in treatment, tumor characteristics, and gene expression signatures. Young patients presented more aggressive clinico-pathologic features such as higher histological grade, more frequent lymph node metastasis involvement, and estrogen receptor negativity. Accordingly, age below 40 years was associated with lower mRNA expression of the estrogen- and progesterone receptors, encoded by ESR1 and PGR, a higher proportion of the basal-like subtype, and increased transcription patterns reflecting stemness. Young breast cancer patients showed reduced survival, also within the basal-like subtype. We observed age-related differences in treatment, with more patients receiving chemotherapy among the young. Our results confirm a more challenging disease in young patients with breast cancer despite the more abundant use of chemotherapy. This argues for increased attention to young patients in current management and future research in breast cancer.

Indexed as

Breast NeoplasmsAdultAge FactorsEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneTranscriptomeYoung AdultEstrogen Receptor alphaReceptors, EstrogenReceptors, ProgesteroneBreast CancerStemnessSurvivalTreatmentYoung Age

Identifiers

PMID39955428
PMCPMC11830014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.